Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Gap Inc V.GAP


Primary Symbol: GAP

The Gap, Inc. is a specialty apparel company in America. The Company offers apparel, accessories and personal care products for women, men and children. Its Old Navy, Gap, Banana Republic, and Athleta brands offer clothing, accessories and lifestyle products for men, women and children. It is an omni-channel retailer, with sales to customers both in stores and online, through Company-operated and franchise stores, websites, and third-party arrangements. Its omni-channel services, including buying online pick-up in store, order-in-store, find-in-store, and ship-from-store, as well as enhanced mobile-enabled experiences, are tailored across its collection of brands. Gap includes adult apparel and accessories, GapKids, babyGap, Gap Maternity, GapBody, and GapFit collections. Banana Republic is a premium lifestyle retailer celebrating exploration and self-expression through timeless quality, versatile fabrics, and exceptionally made womenswear, menswear, and home designs.


NYSE:GAP - Post by User

Bullboard Posts
Comment by BlackRussian1on Aug 06, 2009 9:28am
314 Views
Post# 16195428

RE: News out

RE: News outThis is HUGE news, even better then I had expected. Dr. Vanderhyden is one of the most respected oncologists in the field of Ovarian cancer and for her to say " We are very pleased that the data CLEARLY show an impact of this peptide on some of our most aggressive ovarian cancer cell lines." is huge for PharmaGap. Now I know why OHRI is moving ahead with further studies. PharmaGap's drug seems to working where all other Ovarian cancer drugs are not. This news is not only great for the investor but also for many women who in the future may find themselves with this extreme cancer......
Bullboard Posts